Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
181-200 of 998 trials

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Cancer Treatment Continuation Study

We are offering ongoing treatment for cancer patients who participated in earlier studies. This study checks the safety of the therapy while ensuring patients have access to their treatment.

Cancer Treatment Continuation>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Fetal and Neonatal Alloimmune Thrombocytopenia: Nipocalimab Study

We are testing nipocalimab in pregnant individuals at risk of FNAIT to see if it can lower the chances of severe complications for the baby. This study compares the treatment to a placebo to evaluate its effectiveness.

Neonatal Alloimmune Thrombocytopenia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

HER2-Positive Breast Cancer: GLSI-100 Treatment Study

We are testing a new peptide treatment for patients with HER2-positive breast cancer at high risk of recurrence after standard therapies. The study aims to see if it improves outcomes compared to a placebo.

Breast CancerHER2 Positive Breast Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Dupilumab for Young Children with Uncontrolled Asthma

We are studying whether dupilumab can help reduce severe asthma attacks in children aged 2 to under 6 years. The trial will also evaluate the safety and tolerability of this treatment.

Asthma and Wheezing1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteAllergologyPediatricsPulmonology

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Multiple Sclerosis: Frexalimab vs. Teriflunomide

We are studying a new medication, frexalimab, for adults with relapsing forms of multiple sclerosis. The goal is to see if it works better than teriflunomide in reducing relapses and improving quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Frexalimab for Nonrelapsing Secondary Progressive Multiple Sclerosis

We are studying whether frexalimab can help delay disability progression in adults with nonrelapsing secondary progressive multiple sclerosis. The trial also examines its effects on quality of life and safety.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cervical Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for women and young adults with high-risk locally advanced cervical cancer after initial treatment. This trial compares volrustomig to a placebo to see if it improves health outcomes.

Locally Advanced Cervical CancerConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteOncology

CMV Prevention in Lung Transplant Recipients: Letermovir Study

We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.

Lung Transplant Patients (D+/R-)1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology

Head and Neck Cancer: Pembrolizumab with Radiotherapy

We are studying if adding radiotherapy to pembrolizumab helps patients with limited spread of head and neck cancer live longer and feel better. This trial focuses on those with a specific type of cancer and aims to compare treatment effects and safety.

Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Rosuvastatin for Preventing Venous Thromboembolism Recurrence

We are studying whether generic rosuvastatin can help prevent further blood clots in patients with a history of venous thromboembolism. We will also look at its safety and effects on bleeding and other vascular events.

Deep Vein ThrombosisPulmonary EmbolismVenous Thromboembolism>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyHematology

Duchenne Muscular Dystrophy: GIVINOSTAT Study

We are evaluating the long-term safety and effects of GIVINOSTAT in patients with Duchenne Muscular Dystrophy who have previously been treated with this drug. The study aims to understand its impact on muscle strength, respiratory function, and daily life.

Duchenne Muscular Dystrophy3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

aHUS: Switching to Iptacopan Treatment

We are studying whether switching from anti-C5 antibody therapy to iptacopan can help people with aHUS avoid complications. The trial will also assess the safety and effects on blood and kidney health.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyNephrology

Advanced Non-Small Cell Lung Cancer: THIO with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining THIO and cemiplimab for people with advanced non-small cell lung cancer. This trial aims to find out if this combination works better than THIO alone for patients who have already been treated.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Focal Segmental Glomerulosclerosis: DMX-200 Treatment Study

We are studying the effects of DMX-200 on kidney function in patients with focal segmental glomerulosclerosis who are taking an angiotensin II receptor blocker. This trial will help us understand its safety and effectiveness compared to standard treatments.

Focal Segmental Glomerulosclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Hepatocellular Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a combination of two medications for people with advanced liver cancer who have not had prior treatment. The goal is to find the best dose and assess safety and effectiveness.

Metastatic Liver Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology